C12N 2310/153
With the aid of a protein
Official title: with the aid of a protein, e.g. recombinase
C12N2310/153 (With the aid of a protein) appears on 14 US grants and 11 published applications in this corpus.
Search patents in C12N- Granted patents
- 14
- Published applications
- 11
- Assignees
- 12
- Inventors
- 42
- Latest grant
- 8 Apr 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 1 |
| 2003 | 1 | 0 |
| 2004 | 0 | 0 |
| 2005 | 1 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 1 | 1 |
| 2020 | 0 | 2 |
| 2021 | 0 | 2 |
| 2022 | 0 | 0 |
| 2023 | 1 | 1 |
| 2024 | 1 | 0 |
| 2025 | 2 | 2 |
By publication year. Applications have been published since 2001.
Recent patents
- Engineered multi-component system for identification and characterisation of T-cell receptors and T-cell antigens8 Apr 2025US 12,270,047 B2Genovie AB
- Inducible, tunable, and multiplex human gene regulation using CRISPR-Cpf121 Jan 2025US 12,202,861 B2The General Hospital Corporation
- Engineered multi-component system for identification and characterisation of T-cell receptors and T-cell antigens18 Jun 2024US 12,012,610 B2Genovie AB
- Inducible, tunable, and multiplex human gene regulation using CRISPR-Cpf16 Jun 2023US 11,667,677 B2The General Hospital Corporation
- Compositions and methods for enhancing homologous recombination1 Oct 2019US 10,428,327 B2Life Technologies Corporation
- Engineered multi-component system for identification and characterisation of t-cell receptors and t-cell antigens25 Sep 2025US 2025/0297211 A1Genovie AB
- Triple-stranded nucleic acid comprising tfo, kits and methods for detecting target sequence by using tfo6 Feb 2025US 2025/0043277 A1Chang Gung University
- Inducible, Tunable, and Multiplex Human Gene Regulation Using CRISPR-Cpf128 Dec 2023US 2023/0416310 A1The General Hospital Corporation
- Inducible, Tunable, and Multiplex Human Gene Regulation Using CRISPR-Cpf17 Oct 2021US 2021/0309701 A1The General Hospital Corporation
- Method for the generation of a multivalent, multispecific antibody expressing cells by targeted integration of multiple expression cassettes in a defined organization13 May 2021US 2021/0139561 A1Hoffmann-La Roche Inc.
Most cited
By later US patents
- Locked nucleic acid hybrids and methods of use128US 6,977,295 B2Invitrogen Corporation · 2005
- Crosslinking oligonucleotides38US 5,849,482 AEpoch Pharmaceuticals, Inc. · 1998
- Cloning of the recA gene from thermus aquaticus YT-125US 5,510,473 AThe United States of American as represented by the Secretary of Health and Human Services · 1996
- Method of targeting DNA22US 5,460,941 AThe United States of America, as represented by the Secretary, Department of Health and Human Services · 1995
- Targeted mutagenesis in living cells using modified oligonucleotides8US 5,935,830 AEpoch Pharmaceuticals, Inc. · 1999